Serum MCP-1 and Osteopontin May Predict Early Renal Injury in Gout: Study
Written By : Dr. Shravani Dali
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-04-01 15:30 GMT | Update On 2025-04-02 06:46 GMT
Advertisement
According to a new research the combination of serum Monocyte Chemoattractant Protein-1 (MCP-1) and Osteopontin (OPN) has a high diagnostic value in detecting early renal injury in patients with gout.
A study was done to explore the changes in serum Monocyte chemoattractant protein-1 (MCP-1) and Osteopontin (OPN) in gout patients and their diagnostic value for early renal injury. In this research, 174 gout patients (January 2022-October 2024) were divided into the early renal injury group (50 cases) and non-early renal injury group (124 cases). Additionally, 169 healthy individuals were included as controls.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.